Infliximab for the treatment of extensive plaque psoriasis--regulation, cost and reimbursement.
Rabinovich
Mordi
M
Fainaru
Menahem
M
D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use*; D020811:Biomedical Technology / Q000191:economics; D003879:Dermatologic Agents / Q000191:economics / Q000627:therapeutic use*; D004059:Diffusion of Innovation; D016527:Drug Costs; D006801:Humans; D000069285:Infliximab; D007557:Israel; D009313:National Health Programs / Q000191:economics / Q000331:legislation & jurisprudence*; D011565:Psoriasis / Q000188:drug therapy*
D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D000069285:Infliximab